Company news
Paradigm Biopharmaceuticals Ltd. news in 2023
Paradigm Biopharmaceuticals Ltd.'s news releases, calls and decks from 2023, newest first.
Security Class Reinstatement to Quotation PARO
November 27, 2023
Successful completion of Retail Entitlement Offer
November 23, 2023
Security Class Suspension from Quotation PARO
November 20, 2023
Paradigm to Recommence Trading
October 31, 2023
Replacement Entitlement Offer and Placement Prospectus
October 31, 2023
PAR Successful Placement and Fully Underwritten ANREO
October 31, 2023
Entitlement Offer and Placement Prospectus
October 29, 2023
Investor Presentation - $30m Capital Raise
October 29, 2023
Paradigm Launches $30M Capital Raising
October 29, 2023
iPPS Increases Cartilage Thickness in Phase 2 Trial
October 17, 2023
Ipps significant OA pain reduction at 12 months
October 9, 2023
2023 Annual Report and Appendix 4E
August 25, 2023
PAR Reports Phase 3 Clinical Trial Update
July 3, 2023
Primary and Secondary endpoints met in MPS I Trial
June 6, 2023
iPPS shows 3-year equivalent durability in OA Canine Study
May 31, 2023
iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
April 3, 2023
Decks in 2023
- Investor Presentation (October 2023)
Investor deck · 38 slides · Oct 30, 2023
- NWR Virtual Healthcare Conference (March 2023)
Conference · 18 slides · Mar 22, 2023
- 41st Annual J.P. Morgan Healthcare Conference (January 2023)
Conference · 21 slides · Jan 11, 2023